Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909706 | 0.88 | CDK8 (0.50) | GRNSORT1GAAMAPK13MAPK12 | |
| SCHEMBL12789824 | 0.87 | MAPK14 (0.49) | GRNSORT1GAAMAPK13MAPK12 | |
| SCHEMBL12789821 | 0.85 | GRN (0.43) | GRNSORT1GAAMAPK13MAPK12 | |
| SCHEMBL9906368 | 0.85 | PRKCZ (0.51) | GRNSORT1GAAMAPK13MAPK12 | |
| SCHEMBL14129178 | 0.85 | PTGS1 (0.59) | GRNSORT1GAAALDH1A1 | |
| SCHEMBL12789819 | 0.85 | MAPK13 (0.48) | GRNSORT1GAAMAPK13MAPK12 | |
| SCHEMBL25510561 | 0.85 | TRPV1 (0.47) | GRNSORT1GAAMAPK13MAPK12 | |
| SCHEMBL12789816 | 0.84 | MAPK14 (0.55) | GRNSORT1GAAMAPK13MAPK12 | |
| SCHEMBL9906367 | 0.83 | MAPK14 (0.52) | GRNSORT1GAAMAPK13MAPK12 | |
| SCHEMBL12705326 | 0.80 | GRN (0.62) | GRNSORT1GAAMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655239-B2 | Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof | Shanghai Institute of Material Medica, Chinese Academy of Sciences (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655239-B2 | Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof | Shanghai Institute of Material Medica, Chinese Academy of Sciences (CN) | 2023-05-23 | — | — | US | disclosed |
| EP-4001267-A1 | FUSED RING PYRIMIDINE AMINO COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2022-05-25 | — | — | EP | disclosed |
| US-9540372-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-9155737-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-10-13 | — | — | US | disclosed |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-8912191-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-12-16 | — | — | US | disclosed |
| US-20140121212-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2014-05-01 | — | — | US | disclosed |
| US-8546387-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-09-20 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8198308-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-7531560-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | GRN 2202/4885SORT1 3738/4885GAA 2889/4885 |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | GRN 2202/4885SORT1 3738/4885GAA 2889/4885 |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | GRN 2202/4885SORT1 3738/4885GAA 2889/4885 |
| US-20140121212-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | GRN 2202/4885SORT1 3738/4885GAA 2889/4885 |
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | GRN 1532/4885SORT1 3054/4885GAA 773/4885 |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | GRN 2202/4885SORT1 3738/4885GAA 2889/4885 |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | BRAF, NRAS, ARAF | GRN 3128/4885SORT1 3257/4885GAA 939/4885 |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | GRN 1532/4885SORT1 3054/4885GAA 773/4885 |
| US-11655239-B2 | Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof | DDR2, DDR1, DOCK2 | GRN 2219/4885SORT1 3916/4885GAA 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.